ALK Actualización en terapias dirigidas en CPNM ALK+

Previous Page

Next Page

Page Background

Should we select ALK TKI sequence ...?

•

By clinical characteristics …

•

presence of brain metastases ?

•

Toxicity profile?

•

By molecular characteristics …

•

fusión variant ?

•

type of resistance mutation?